GAITHERSBURG, Md., Feb. 22 /PRNewswire-FirstCall/ -- Iomai Corporation announced that its Chief Scientific Officer, Gregory Glenn, M.D., will speak today at the 1st Annual Skin Summit in Philadelphia. Dr. Glenn's presentation, "Transcutaneous Immunization: Towards Commercialization," will take place during a 2 p.m. session on transcutaneous vaccine delivery.
The conference is being held at the Park Hyatt hotel.
Dr. Glenn, the founder of Iomai, developed the company's proprietary TCI (transcutaneous immunization technology) technology. TCI serves as the basis for the skin-patch-based vaccines and immunostimulants that Iomai is developing, including vaccines for seasonal influenza and travelers' diarrhea now in clinical testing. In addition, the company has been awarded a $128 million contract by the Department of Health and Human Services to develop a dose-sparing patch for use with a pandemic influenza vaccine.
ABOUT IOMAI CORPORATION
Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent E. coli-related travelers' diarrhea. For more information on Iomai, please visit www.iomai.com.
Iomai CorporationCONTACT: Russell P. Wilson, Senior Vice President, Chief Financial Officerand General Counsel of Iomai Corporation, +1-301-556-4478, orinvestors@iomai.com; or Brian Reid of WeissComm Partners, Inc.,+1-703-402-3626, or breid@weisscommpartners.com, for Iomai
Web site: http://www.iomai.com//
